The purpose of this research study is to learn about levels of antiretroviral drug levels and response to HIV virus in the genital tract of women who are post-menopausal. The investigators in this study think that the levels of hormones post-menopausal HIV-infected women may have in their bodies may affect the levels of antiretroviral drug, and therefore affect how much HIV virus they have in their bodies. Since women who have already gone through menopause have different levels of hormones, such as estrogen, than women who are pre-menopausal, the investigators would like to check the levels of antiretroviral drugs in their blood, their genital secretions, and their genital tissue.

Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).

Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).

Other Names:

Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine)

Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV

Emtricitabine: FTC, Emtriva

Abacivir: Ziagen

Tenofovir: TDF, Viread

Efavirenz: Sustiva, Stocrin

Lopinavir/Ritonavir: Kaletra, Aluvia

Atazanavir: Reyataz

Ritonavir: Norvir

Maraviroc: Selzentry

Raltegravir: MK-0518, Isentress

Etravirine: TMC-125, Intelence

Group 2

12 pre-menopausal HIV-infected women

Drug: ARV regimen chosen by treating physician

Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).

Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).

Other Names:

Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine)

Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV

Emtricitabine: FTC, Emtriva

Abacivir: Ziagen

Tenofovir: TDF, Viread

Efavirenz: Sustiva, Stocrin

Lopinavir/Ritonavir: Kaletra, Aluvia

Atazanavir: Reyataz

Ritonavir: Norvir

Maraviroc: Selzentry

Raltegravir: MK-0518, Isentress

Etravirine: TMC-125, Intelence

Detailed Description:

Purpose: To longitudinally quantify systemic and genital tract antiretroviral pharmacokinetics and viral responses in HIV-infected post-menopausal women. These parameters will be compared to pre-menopausal women to determine if the absence or presence of estrogen influences treatment responses and infectiousness of HIV.

Participants: 30 post-menopausal and 12 pre-menopausal HIV-infected women Procedures (methods): First dose, steady state, and longitudinal pharmacokinetics of the most commonly prescribed antiretroviral agents will be assessed in the systemic and genital tract compartments in a cohort of post- and pre-menopausal HIV-infected women. Concurrent blood plasma and genital secretions HIV RNA will be measured. Systemic and genital tract virologic responses will be correlated with antiretroviral concentrations and with each other.

Eligibility

Ages Eligible for Study:

19 Years and older

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Subjects will primarily be recruited from the UNC Infectious Disease Clinic and the Wake County HIV Clinic.

Criteria

Inclusion Criteria:

HIV-infected women >18 years of age

There are no specific entry criteria for CD4+ T-cell counts and plasma HIV RNA.

Menopause status will be determined at screening.

Post-menopausal will be defined as the cessation of menses for >12 months (or undergone a bilateral oophorectomy with or without a hysterectomy) AND a FSH >25 miu/mL and estradiol level <20 pg/mL establishing both physiological and biochemical evidence of menopause.

Pre-menopausal women must have regular cycles without peri-menopausal vasomotor symptoms and not receiving exogenous hormones.

Women may be changing to a new regimen because of virologic failure or intolerability. Women in whom resistance testing is available, two or more drugs to which the virus is susceptible needs to be included in the proposed treatment regimen.

Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).

Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI). Samples will be stored so that the pharmacokinetics of these agents can be evaluated in future studies once the assays are available in our lab.

Women must be free from sexually transmitted infections (STI's) at the time of enrollment.

Women must be able to abstain from douching and sexual activity for 72 hours prior to all study visits.

Subjects must be willing to have genital tract samples taken.

Exclusion Criteria:

Women currently receiving medication with known drug-drug interaction with the ARVs under study.

Women currently receiving any exogenous hormone therapy (contraception, estrogen replacement therapy or androgen supplements). Women must be off all exogenous hormone therapy for > 16 weeks prior to enrollment.

Women who are pregnant or breast-feeding.

Women with a hemoglobin <9.0g/dL and/or hematocrit <28%.

Women unable to complete, or have a caretaker complete, a dose administration card.

Women who, in the judgement of the investigator, are unable to comply with the protocol requirements.

Women who are unable to give written informed consent.

Women who cannot comply with abstaining from intercourse or douching 48 hours prior to study examination.

Male or transgender individuals.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00666055